Project description DEENESFRITPL Medical device for preserving organ transplants Organ transplantation is a life-saving procedure for many people facing terminal diseases associated with end-stage organ failure. However, there are many impediments to the success of the procedure including organ preservation during transport. Conventionally, organs are preserved under cold conditions, but this is not optimal for all types of grafts. To address this medical need, the EU-funded NORMOPERF project proposes to develop an innovative medical device that can preserve organ grafts under physiological conditions including temperature using perfusion. The device is expected to improve the logistics of transplantation as well as the quality of organs with obvious benefits for the outcome of the procedure. Show the project objective Hide the project objective Objective EBERS is a leading company in the field of bioreactors and cell culture systems, with a wide international presence in Europe, USA, Australia, and Asia. In the NORMOPERF project we go a step further by targeting the organ transplantation field by bringing to the healthcare market a new portable device for extracorporeal organ preservation based on a patented technology (P201730030).Organ transplantation is in many cases the only effective therapy for end-stage organ failure. However, it is estimated that only 10% of the global organ needs are covered. Traditionally, only organs obtained in optimal conditions have been considered for transplantation. However, organ lack is leading to the increased use of suboptimal grafts (e.g. non-heart beating donors), which poses new challenges. The most important hurdle preventing the clinical use of suboptimal organs is the limitation of static cold preservation (SCP). SCP is well suited for optimal grafts, but not for suboptimal ones since (i) it allows short preservation times (2-20 h), (ii) it does not provide information about the organ viability and (iii) it additionally damages the organ due to ischemia-reperfusion. The solution proposed by EBERS is a new portable medical device based on normothermic perfusion, capable of maintaining human organs in a viable state for sustained periods under physiological conditions. The NORMOPERF project will offer the clinical community a new device for organ preservation that will contribute to increasing the number of organs available for transplantation by making possible the clinical use of a significant part of the suboptimal organs that are currently not even considered for transplantation. Thus, the use of our technology will allow increasing x2-3 the current transplant rates in the short term.According to our conservative estimations, the €2.57 Mill required for this project will mean €21.3M cumulative EBITDA in 5-years, representing a ROI of 723%. Fields of science natural sciencescomputer and information sciencesartificial intelligenceengineering and technologymechanical engineeringmanufacturing engineeringengineering and technologyenvironmental biotechnologybioremediationbioreactorsmedical and health sciencesclinical medicinetransplantationsocial sciencespolitical sciencespublic administration Keywords Organ preservation Organ transplant Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-2-2016-2017 Funding Scheme SME-2 - SME instrument phase 2 Coordinator EBERS MEDICAL TECHNOLOGY SL Net EU contribution € 2 570 850,00 Address Avenida de madrid 117 5 a 50010 Zaragoza Spain See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Noreste Aragón Zaragoza Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 570 850,00